Interventional Cardiovascular Surgery

Don't miss this session focusing on angina by exploring 5 different cases, including a challenging graft aneurysm, a vein graft perforation after CABG not related to PCI and an unusual case of tortuosity in a two-year-old child...

Thanks to these seven clinical cases, you will be able to learn how to manage risky and complex interventions, including a case of complex triple bifurcation lesions, a high-risk PCI case and a successful kissing balloon technique in transradial PCI.

The purpose of the prespecified subanalysis of the EXCEL (Evaluation of XIENCE versus Coronary artery bypass surgery for Effectiveness of Left main revascularization) trial was to determine whether the outcomes remained consistent regardless of geography.

The study by Zahr et al. reports the results of an interim analysis assessing procedural and clinical outcomes at 30-day in 15 patients treated with the newly developed Medtronic Intrepid 35-F trans-femoral transcatheter mitral valve replacement (TMVR) system.

Vijay Kunadian provides summaries of study designs and findings in Interventional Cardiology released at the 2021 virtual edition of the American Heart Association Congress. View an infographic of the AVATAR late-breaking trial by Ali Nazmi Calik.

Although TAVI is an accepted alternative to surgery in patients with severe aortic stenosis who are at high surgical risk, less is known about long-term comparative outcomes among patients with aortic stenosis who are at intermediate surgical risk. P. Redaelli & M. Pighi review the SURTAVI trial...

Professor David J. Cohen presented the results of the economic outcomes of the PARTNER 3 trial on Friday, 5 November, in the Late-Breaking Trial session of the Transcatheter Cardiovascular Therapeutics Congress 2021. Giuseppe Biondi-Zoccai provides his analysis of this study.

Mirvat Alasnag reviews the OPTIMUM trial, presented by David E. Kandzari, which reports outcomes in a subset of patients who are increasingly seen in modern day catheterization laboratories. It is noteworthy that 1 in 5 patients with left main or multivessel disease are considered surgically ineligible.

In conducting the ACTIVATION trial, Redwood and colleagues seek to complement the existing literature with high-level evidence on whether percutaneous coronary intervention (PCI) prior to TAVR is non-inferior to conservative (no PCI) management.

Through this registry-based analysis, the authors sought to assess short and long-term outcomes of revascularisation in a latecomer STEMI population presenting between 12 to 48 hours of symptom onset.